vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and ONE Group Hospitality, Inc. (STKS). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $207.0M, roughly 1.2× ONE Group Hospitality, Inc.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -3.1%, a 14.2% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -6.7%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-329.0K). Over the past eight quarters, ONE Group Hospitality, Inc.'s revenue compounded faster (56.1% CAGR vs 34.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Target Hospitality is a company that provides workforce lodging and other temporary, modular housing used for oil, gas and mining operations; large-scale events; and disaster relief. Target Hospitality is based in The Woodlands, Texas, and also has offices in Williston, North Dakota; Denver, Colorado; Calgary, Alberta.
ANIP vs STKS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $207.0M |
| Net Profit | $27.5M | $-6.4M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 2.2% |
| Net Margin | 11.1% | -3.1% |
| Revenue YoY | 29.6% | -6.7% |
| Net Profit YoY | 367.5% | -531.8% |
| EPS (diluted) | $1.14 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $207.0M | ||
| Q3 25 | $227.8M | $180.2M | ||
| Q2 25 | $211.4M | $207.4M | ||
| Q1 25 | $197.1M | $211.1M | ||
| Q4 24 | $190.6M | $221.9M | ||
| Q3 24 | $148.3M | $194.0M | ||
| Q2 24 | $138.0M | $172.5M | ||
| Q1 24 | $137.4M | $85.0M |
| Q4 25 | $27.5M | $-6.4M | ||
| Q3 25 | $26.6M | $-76.7M | ||
| Q2 25 | $8.5M | $-10.1M | ||
| Q1 25 | $15.7M | $975.0K | ||
| Q4 24 | $-10.3M | $1.5M | ||
| Q3 24 | $-24.2M | $-9.3M | ||
| Q2 24 | $-2.3M | $-7.3M | ||
| Q1 24 | $18.2M | $-2.1M |
| Q4 25 | 14.1% | 2.2% | ||
| Q3 25 | 15.9% | -4.4% | ||
| Q2 25 | 6.6% | 0.3% | ||
| Q1 25 | 13.3% | 5.1% | ||
| Q4 24 | -2.3% | 5.5% | ||
| Q3 24 | -13.8% | -1.9% | ||
| Q2 24 | 3.7% | 0.6% | ||
| Q1 24 | 14.8% | -0.7% |
| Q4 25 | 11.1% | -3.1% | ||
| Q3 25 | 11.7% | -42.6% | ||
| Q2 25 | 4.0% | -4.9% | ||
| Q1 25 | 8.0% | 0.5% | ||
| Q4 24 | -5.4% | 0.7% | ||
| Q3 24 | -16.3% | -4.8% | ||
| Q2 24 | -1.7% | -4.3% | ||
| Q1 24 | 13.2% | -2.4% |
| Q4 25 | $1.14 | $-0.50 | ||
| Q3 25 | $1.13 | $-2.75 | ||
| Q2 25 | $0.36 | $-0.59 | ||
| Q1 25 | $0.69 | $-0.21 | ||
| Q4 24 | $-0.45 | $-0.18 | ||
| Q3 24 | $-1.27 | $-0.53 | ||
| Q2 24 | $-0.14 | $-0.38 | ||
| Q1 24 | $0.82 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $4.2M |
| Total DebtLower is stronger | — | $354.2M |
| Stockholders' EquityBook value | $540.7M | $-75.8M |
| Total Assets | $1.4B | $884.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $4.2M | ||
| Q3 25 | $262.6M | $5.5M | ||
| Q2 25 | $217.8M | $4.7M | ||
| Q1 25 | $149.8M | $21.4M | ||
| Q4 24 | $144.9M | $27.6M | ||
| Q3 24 | $145.0M | $28.2M | ||
| Q2 24 | $240.1M | $32.2M | ||
| Q1 24 | $228.6M | $15.4M |
| Q4 25 | — | $354.2M | ||
| Q3 25 | — | $355.0M | ||
| Q2 25 | — | $347.4M | ||
| Q1 25 | — | $348.3M | ||
| Q4 24 | — | $348.3M | ||
| Q3 24 | — | $349.1M | ||
| Q2 24 | — | $350.0M | ||
| Q1 24 | — | $73.5M |
| Q4 25 | $540.7M | $-75.8M | ||
| Q3 25 | $505.8M | $-61.5M | ||
| Q2 25 | $436.8M | $23.0M | ||
| Q1 25 | $418.6M | $40.5M | ||
| Q4 24 | $403.7M | $45.9M | ||
| Q3 24 | $405.9M | $51.4M | ||
| Q2 24 | $455.8M | $68.1M | ||
| Q1 24 | $452.0M | $68.3M |
| Q4 25 | $1.4B | $884.2M | ||
| Q3 25 | $1.4B | $879.5M | ||
| Q2 25 | $1.3B | $935.7M | ||
| Q1 25 | $1.3B | $956.0M | ||
| Q4 24 | $1.3B | $960.1M | ||
| Q3 24 | $1.3B | $953.5M | ||
| Q2 24 | $920.8M | $945.9M | ||
| Q1 24 | $914.5M | $309.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 15.07× | ||
| Q1 25 | — | 8.61× | ||
| Q4 24 | — | 7.59× | ||
| Q3 24 | — | 6.79× | ||
| Q2 24 | — | 5.14× | ||
| Q1 24 | — | 1.08× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $13.1M |
| Free Cash FlowOCF − Capex | $29.1M | $-329.0K |
| FCF MarginFCF / Revenue | 11.8% | -0.2% |
| Capex IntensityCapex / Revenue | 0.5% | 6.5% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-27.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $13.1M | ||
| Q3 25 | $44.1M | $5.9M | ||
| Q2 25 | $75.8M | $2.8M | ||
| Q1 25 | $35.0M | $8.5M | ||
| Q4 24 | $15.9M | $18.5M | ||
| Q3 24 | $12.5M | $19.1M | ||
| Q2 24 | $17.4M | $-3.8M | ||
| Q1 24 | $18.3M | $10.4M |
| Q4 25 | $29.1M | $-329.0K | ||
| Q3 25 | $38.0M | $-6.1M | ||
| Q2 25 | $71.8M | $-15.0M | ||
| Q1 25 | $32.5M | $-5.8M | ||
| Q4 24 | $13.5M | $733.0K | ||
| Q3 24 | $7.7M | $287.0K | ||
| Q2 24 | $13.0M | $-23.0M | ||
| Q1 24 | $13.7M | $-5.4M |
| Q4 25 | 11.8% | -0.2% | ||
| Q3 25 | 16.7% | -3.4% | ||
| Q2 25 | 34.0% | -7.2% | ||
| Q1 25 | 16.5% | -2.7% | ||
| Q4 24 | 7.1% | 0.3% | ||
| Q3 24 | 5.2% | 0.1% | ||
| Q2 24 | 9.4% | -13.3% | ||
| Q1 24 | 10.0% | -6.4% |
| Q4 25 | 0.5% | 6.5% | ||
| Q3 25 | 2.7% | 6.7% | ||
| Q2 25 | 1.9% | 8.6% | ||
| Q1 25 | 1.3% | 6.8% | ||
| Q4 24 | 1.3% | 8.0% | ||
| Q3 24 | 3.2% | 9.7% | ||
| Q2 24 | 3.2% | 11.1% | ||
| Q1 24 | 3.3% | 18.6% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | 8.76× | ||
| Q4 24 | — | 12.54× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
STKS
| Benihanas | $111.3M | 54% |
| Steakhouse Restaurant | $59.2M | 29% |
| Grill Concepts | $32.3M | 16% |
| Other | $4.2M | 2% |
